MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.300
-0.020 (-1.52%)
At close: Jun 22, 2026, 4:00 PM EDT
1.305
+0.005 (0.38%)
After-hours: Jun 22, 2026, 4:10 PM EDT
MediciNova Revenue
MediciNova had revenue of $186.98K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $596.64K. In the year 2025, MediciNova had annual revenue of $409.66K.
Revenue (ttm)
$596.64K
Revenue Growth
n/a
P/S Ratio
107.25
Revenue / Employee
$99,440
Employees
6
Market Cap
63.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 409.66K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 4.04M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 6.00M | 5.20M | 648.00% |
| Dec 31, 2012 | 802.58K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | 263.88K | -540.19K | -67.18% |
| Dec 31, 2005 | 804.07K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeyondSpring | 1.88M |
| Seres Therapeutics | 1.15M |
| ImageneBio | 800.00K |
| iBio, Inc. | 300.00K |
| eXoZymes | -700.00 |
MNOV News
- 14 days ago - MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment - GlobeNewsWire
- 27 days ago - MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) - GlobeNewsWire
- 27 days ago - MediciNova Slides: Corporate presentation - Filings
- 5 weeks ago - MediciNova Quarterly report: Q1 2026 - Filings
- 7 weeks ago - MediciNova Proxy statement: Proxy filing - Filings
- 7 weeks ago - MediciNova Proxy statement: Proxy filing - Filings
- 2 months ago - MediciNova’s peer-reviewed ibudilast study advances clinical translation - TheFly
- 2 months ago - New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation - GlobeNewsWire